Shots:
- Japan’s MHLW has accepted sNDA of Arexvy RSV vaccine for adults aged 18-49yrs. at increased risk, expanding its use beyond those aged ≤50yrs.
- Submission was based on P-IIIb trial (n=1458) assessing non-inferiority & safety of Arexvy RSV vaccine in individuals (18-49yrs.; n=426) compared to adults (≥60yrs.; n=429); an additional cohort (18-49yrs.; n=603) was followed for AEs separate to safety follow up of the initial cohort
- Trial showed non-inferior immunogenicity in individuals (18-49yrs.) who are at increased risk of RSV-LRTD. Safety & reactogenicity aligned with P-III study data that supported initial approval
Ref: GSK| Image: GSK| Press Release
Related News:- Merck and Daiichi Sankyo Report First Patient Dosing with Ifinatamab DXd in P-III (IDeate-Prostate01) Trial for mCRPC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
